Secondary prevention focus Berkeley HeartLab specializes in cardiovascular disease management with a distinctive emphasis on secondary prevention, indicating sales opportunities with clinics and hospitals treating patients with established CVD who require ongoing risk monitoring and therapeutic adjustment.

Comprehensive testing With over 35 clinical diagnostic tests including lipoprotein particle analysis and genetic testing, there is a cross-sell opportunity to expand from lipid testing into broader CV risk assessment and personalized medicine offerings for existing customers.

CLIA-certified lab The high complexity CLIA-certified laboratory credential supports credibility for payer reimbursement discussions and hospital partnerships, aiding sales conversations with institutions seeking compliant, high-quality diagnostic services.

Reimbursement viability Tests may be reimbursed by private insurance and Medicare, suggesting a favorable payer landscape to emphasize in proposals and to encourage adoption among clinicians seeking cost-effective, billable monitoring solutions.

Growth potential Revenue in the mid six figures to lower seven figures range combined with a focus on personalized cardiovascular care positions Berkeley HeartLab as a potential partner for expanding into bundled CV risk management programs and allied diagnostics with strategic healthcare networks.